PURPOSE: Preclinical data showed that trientine, a copper-lowering agent, re-sensitized cancer cells to carboplatin through enhanced human copper transporter 1 (hCtr1) -mediated platinum uptake. EXPERIMENTAL DESIGN: We studied carboplatin and trientine in patients (n = 55; 45 who had failed platinum) with advanced malignancies (Phase I, modified 3 + 3 design). RESULTS: The most common cancers were head and neck (n = 13), non-small cell lung (n = 10) and epithelial ovarian (n = 8). The median number of prior regimens was four. No dose-limiting toxicity or treatment-related deaths were observed at doses up to carboplatin AUC 6 given with trientine. Eight patients achieved stable disease (SD) ≥ 6 months (six platinum failures) and one patient with platinum-resistant ovarian cancer, partial response (PR) (total SD ≥ 6 months/PR = 9, 16.4 %). The mean nadir serum copper level in the nine patients with SD ≥ 6 months/PR was 0.55 μg/mL (95 % CI, 0.34-0.75) versus 1.22 μg/mL (95 % CI, 1.02-1.42) (p < 0.001) in 38 tested patients with progression. In patients who maintained their ceruloplasmin (major copper-carrying protein) levels at 5-15 mg/dL (n = 9), the median progression-free and overall survivals were 9.2 and 15.2 months versus 1.9 (p = 0.001) and 5.7 months (p = 0.033) in patients who did not (n = 38), respectively. CONCLUSIONS: The combination of a copper-lowering agent with carboplatin was well tolerated and associated with antitumor activity, especially in patients in whom copper and/or ceruloplasmin levels were lowered. Further investigation of this strategy for reversing platinum resistance is warranted.
PURPOSE: Preclinical data showed that trientine, a copper-lowering agent, re-sensitized cancer cells to carboplatin through enhanced humancopper transporter 1 (hCtr1) -mediated platinum uptake. EXPERIMENTAL DESIGN: We studied carboplatin and trientine in patients (n = 55; 45 who had failed platinum) with advanced malignancies (Phase I, modified 3 + 3 design). RESULTS: The most common cancers were head and neck (n = 13), non-small cell lung (n = 10) and epithelial ovarian (n = 8). The median number of prior regimens was four. No dose-limiting toxicity or treatment-related deaths were observed at doses up to carboplatin AUC 6 given with trientine. Eight patients achieved stable disease (SD) ≥ 6 months (six platinum failures) and one patient with platinum-resistant ovarian cancer, partial response (PR) (total SD ≥ 6 months/PR = 9, 16.4 %). The mean nadir serum copper level in the nine patients with SD ≥ 6 months/PR was 0.55 μg/mL (95 % CI, 0.34-0.75) versus 1.22 μg/mL (95 % CI, 1.02-1.42) (p < 0.001) in 38 tested patients with progression. In patients who maintained their ceruloplasmin (major copper-carrying protein) levels at 5-15 mg/dL (n = 9), the median progression-free and overall survivals were 9.2 and 15.2 months versus 1.9 (p = 0.001) and 5.7 months (p = 0.033) in patients who did not (n = 38), respectively. CONCLUSIONS: The combination of a copper-lowering agent with carboplatin was well tolerated and associated with antitumor activity, especially in patients in whom copper and/or ceruloplasmin levels were lowered. Further investigation of this strategy for reversing platinum resistance is warranted.
Authors: J Yoshii; H Yoshiji; S Kuriyama; Y Ikenaka; R Noguchi; H Okuda; H Tsujinoue; T Nakatani; H Kishida; D Nakae; D E Gomez; M S De Lorenzo; A M Tejera; H Fukui Journal: Int J Cancer Date: 2001-12-15 Impact factor: 7.396
Authors: Helen H W Chen; Jiang-Jou Yan; Wen-Chung Chen; Macus Tien Kuo; Yu-Hsuan Lai; Wu-Wei Lai; Hsiao-Sheng Liu; Wu-Chou Su Journal: Lung Cancer Date: 2011-07-23 Impact factor: 5.705
Authors: Macus Tien Kuo; Helen H W Chen; Im-Sook Song; Niramol Savaraj; Toshihisa Ishikawa Journal: Cancer Metastasis Rev Date: 2007-03 Impact factor: 9.264
Authors: Helen H W Chen; Wen-Chung Chen; Zhang-Dong Liang; Wen-Bin Tsai; Yan Long; Isamu Aiba; Siqing Fu; Russell Broaddus; Jinsong Liu; Lynn G Feun; Niramol Savaraj; Macus Tien Kuo Journal: Expert Opin Ther Targets Date: 2015-05-25 Impact factor: 6.902
Authors: Mitchell Acland; Noor A Lokman; Clifford Young; Dovile Anderson; Mark Condina; Chris Desire; Tannith M Noye; Wanqi Wang; Carmela Ricciardelli; Darren J Creek; Martin K Oehler; Peter Hoffmann; Manuela Klingler-Hoffmann Journal: Cancers (Basel) Date: 2022-06-02 Impact factor: 6.575